Cardio Diagnostics to Showcase Cardio Risk Platform Addressing 11% of U.S. Healthcare Costs at Four June Conferences
CDIO•Cardio Diagnostics is engaging employers, insurers and healthcare systems at four national benefits conferences this June to present its suite of early cardiovascular risk identification and preventive care solutions. Cardiovascular disease accounted for roughly 11% of U.S. healthcare expenditures in 2020–2021, driving employers’ productivity losses and long-term care costs.
1. Conference Engagement Strategy
Cardio Diagnostics will participate in four national benefits conferences during June, engaging directly with employers, insurers and healthcare administrators to discuss cardiovascular disease prevention, risk assessment and cost management solutions.
2. Early Cardiovascular Risk Detection Suite
The company’s suite combines biomarker testing, predictive algorithms and targeted intervention protocols to identify high cardiovascular risk in asymptomatic individuals and enable earlier, more effective preventive care.
3. Market and Cost Implications
Cardiovascular disease accounted for approximately 11% of U.S. healthcare expenditures in 2020–2021, making it the most expensive major condition and contributing to higher medical costs, lost productivity and long-term care expenses.
4. Stakeholder Benefits
By adopting Cardio Diagnostics’ early detection platform, employers can reduce absenteeism and healthcare spending while insurers may lower claims costs through proactive risk management and targeted preventive interventions.
